“It’s really bone versus breast cancer, is what it really comes down to,” said Dr. Carey of the University of North Carolina. Advertisement Continue reading the main story“It’s an option but not the standard,” said Dr. Eric Winer, director of the breast cancer program at the Dana-Farber Cancer Institute in Boston and an author of the study. The study received funding from the National Cancer Institute, the Canadian Cancer Society Research Institute and Novartis. Using a statistical measure known as the hazard ratio, the risk of a recurrence or of new breast cancer was reduced by 34 percent. Or they can take five years of an aromatase inhibitor after five years of tamoxifen.

Source: New York Times June 05, 2016 11:30 UTC